✦ LIBER ✦

PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL

✍ Scribed by Lisa K. Jennings; David Moliterno; Robert Storey; Edward Hord; Jayaprakash Kotha; Richard Becker; Susan Smyth; Luis Providencia; Tiziano Moccetti; Marco Valgimigli; Jean-Pierre Dery; J.H. Cornel; Gregory Thomas; Kurt Huber; Edmond Chen; John Strony; Tyrus Rorick; Pierluigi Tricoci; Kenneth Mahaffey

Book ID: 118582163
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 95 KB
Volume: 59
Category: Article
ISSN: 1558-3597
DOI: 10.1016/s0735-1097(12)60352-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacodynamic interplay of the P2Y1, P

Pharmacodynamic interplay of the P2Y1, P2Y12, and TxA2 pathways in platelets: The potential of triple antiplatelet therapy with P2Y1 receptor antagonism

✍ Oestreich, Julie H.; Ferraris, Suellen P.; Steinhubl, Steven R.; Akers, Wendell 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 500 KB

EFFECTS OF GLYCOPROTEIN IIB/IIIA INHIBIT

EFFECTS OF GLYCOPROTEIN IIB/IIIA INHIBITORS IN COMBINATION WITH VORAPAXAR, A PLATELET THROMBIN-RECEPTOR ANTAGONIST, AMONG PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES: INSIGHTS FROM THE TRACER TRIAL

✍ Cornel, J.H.; Tricoci, Pierluigi; Horton, john; Moliterno, David; Wallentin, Lar 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Comparison of ticagrelor, the first reve

Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

✍ Stefan James; Axel Åkerblom; Christopher P. Cannon; Håkan Emanuelsson; Steen Hus 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Comparison of ticagrelor, the first reve

✍ Stefan James; Axel Åkerblom; Christopher P. Cannon; Håkan Emanuelsson; Steen Hus 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 139 KB

The in-vitro effects of E5555, a proteas

The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease

✍ Serebruany, Victor L.; Kogushi, Motoji; Dastros-Pitei, Daniela; Flather, Marcus; 📂 Article 📅 2009 🏛 Schattauer 🌐 English ⚖ 101 KB

Safety and feasibility of adjunctive ant

Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial

✍ Jeffrey S. Berger; Matthew T. Roe; C. Michael Gibson; Rakhi Kilaru; Cynthia L. G 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 239 KB